Carasent AB (publ) (OTCPK:APXZF)
$ 0.15 (0%) Market Cap: 157.05 Mil Enterprise Value: 146.68 Mil PE Ratio: 39.48 PB Ratio: 1.96 GF Score: 80/100

Q1 2026 Carasent AB (publ) Earnings Call Transcript

Apr 14, 2026 / 06:00AM GMT
Release Date Price: $0.15

Key Points

Positve
  • Carasent AB (publ) (STU:E0C) reported a strong 16% year-over-year growth in Annual Recurring Revenue (ARR), indicating robust business expansion.
  • The company achieved a high net revenue retention rate of 111%, showcasing strong customer loyalty and upselling capabilities.
  • Profitability improved significantly with an EBITDAC margin of 10%, up from 6% a year ago, and an EBITDA margin of 20%.
  • The launch of Webcur in Germany marks a major milestone, with the potential to expand market presence and drive future growth.
  • Carasent AB (publ) (STU:E0C) is leveraging AI to enhance product functionality and user experience, which could widen the competitive gap with legacy systems.
Negative
  • Consulting revenues declined by 50% from SEK8 million to SEK4 million, contributing to lower overall revenue growth compared to ARR growth.
  • The German operations experienced a decline in revenue due to churn in legacy products, which may continue to impact performance in the short term.
  • The transition to new systems in Germany, such as Webcur, is expected to take time, delaying immediate revenue growth from this market.
  • The healthcare sector's conservative nature and resistance to change pose challenges in accelerating the adoption of new technologies like Medsum.
  • Operational costs related to AI development and hosting are high, impacting short-term profitability despite long-term potential benefits.
Daniel Oehman
Carasent ASA - Chief Executive Officer

Good morning, and welcome to our presentation of the first quarter of 2026. We will start with me giving a company update, and then I will hand over to Svein Martin for more of a financial update.

First, a quick overview of who we are. So our business is to help our customers, who are private hospitals and clinics, to help as many patients as possible. We do this through our HR systems and related products. We're growing rapidly this quarter with 16% ARR growth and with highly recurring revenues in this quarter, it's actually above 95%, and with net revenue retention of 111%.

So looking a little bit more of the highlights of the first quarter. So as I mentioned, we had good ARR growth of 16%, and we continue to scale our business in a good way. In this quarter, we had almost 80% of the growth translating into profitability.

And we've been working in the last couple of years, and this is how we aim to continue working. In the quarter, we have quite low consulting revenues and consulting revenues, they vary between quarters

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot